Viimane versioon :
08/05/2024
Prootonpumba inhibiitor   Esomeprazole sodium  
Süsteravim
Stabiilsus lahustes Stabiilsust mõjutavad tegurid Stabiilsust mõjutavad faktorid Sobimatus Manustamis viis Viited Pdf
   Keemiline struktuur  

Kaubanduslikud nimed erinevates maades   Kaubanduslikud nimed erinevates maades     

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Adptor Mehhiko
Axagon Itaalia
Axiago Rootsi
Cativa Rootsi
Cronopep Kolumbia, Maroko
Eliprot Ecuador
Emune Ecuador
Epral Tšiili
Esio Ecuador
Esmonat India, Türgi
Esoblok Türgi
Esofax Ecuador
Esolium Maroko
Esomep Sveits
Esomeprazol Ecuador, Hispaania, Kolumbia, Rumeenia, Tšiili
Esomeprazole Ameerika ühendriigid
Esopral Itaalia, Rootsi
Esopran Maroko
Esoton Plus Maroko
Esoz India, Kolumbia
Ezole Maroko
Gletop Venetsueela
Inexium Prantsusmaa
Milenium Ecuador
Nexiam Belgia, Luksemburg
Nexium Ameerika ühendriigid, Araabia Ühendemiraadid, Argentiina, Ecuador, Egiptus, Hispaania, Iirimaa, Island, Itaalia, Kolumbia, Kreeka, Malaisia, Mehhiko, Norra, Portugal, Rootsi, Rumeenia, Saksamaa, Saudi Araabia, Suurbritannia, Sveits, Tšiili, Türgi, Venetsueela
Redica Rootsi
Refexxin Rootsi
Viited   Süsteravim   Viited : Esomeprazole sodium  
Tüüp Avaldamine
1506 Ajaleht Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D.
Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.
EJHP 2015 ;22:107-112.
1508 Ajaleht Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
2262 Ajaleht Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Ajaleht Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2270 Ajaleht Kupiec TC, Aloumanis V, Ben M, Trissel LA, Chan P, Patterson J.
Physical and chemical stability of esomeprazole sodium solutions.
Ann Pharmacotherapy 2008 ; 42, 9: 1247-1251.
2284 Labor Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics
Astra Zenaca 2007
2311 Ajaleht Kambia N.K, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C.
Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
J Clin Pharm Ther 2009 ; 34: 25-31.
3249 Ajaleht Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Ajaleht Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332 Labor Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3372 Ajaleht Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3429 Ajaleht Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S.
Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration
Am J Health-Syst Pharm 2015 ; 72:483-486
3827 Plakat Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Plakat Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Plakat So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3879 Ajaleht Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948 Ajaleht Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
4055 Ajaleht Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Ajaleht Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433 Ajaleht Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4465 Ajaleht Foushee A, Meredith P, Fox Laura, Wilder A.
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4528 Ajaleht Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4650 Labor Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4801 Ajaleht Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales